These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25431946)

  • 21. The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene.
    Licandro SA; Crippa L; Pomarico R; Perego R; Fossati G; Leoni F; Steinkühler C
    Skelet Muscle; 2021 Jul; 11(1):19. PubMed ID: 34294164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Givinostat: First Approval.
    Lamb YN
    Drugs; 2024 Jul; 84(7):849-856. PubMed ID: 38967716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors.
    Cerquone Perpetuini A; Giuliani G; Reggio A; Cerretani M; Santoriello M; Stefanelli R; Palma A; Vumbaca S; Harper S; Castagnoli L; Bresciani A; Cesareni G
    Sci Rep; 2020 Mar; 10(1):5363. PubMed ID: 32210313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic regulation of skeletal muscle development and differentiation.
    Bharathy N; Ling BM; Taneja R
    Subcell Biochem; 2013; 61():139-50. PubMed ID: 23150250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment.
    Colussi C; Banfi C; Brioschi M; Tremoli E; Straino S; Spallotta F; Mai A; Rotili D; Capogrossi MC; Gaetano C
    Proteomics Clin Appl; 2010 Jan; 4(1):71-83. PubMed ID: 21137017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of therapy for Duchenne muscular dystrophy.
    Zhang S; Xie H; Zhou G; Yang Z
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Feb; 21(2):194-203. PubMed ID: 17357471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steroid Responsiveness in Duchenne Muscular Dystrophy - Predictive Value of Epigenetic Regulator Histone Deacetylase 2.
    Pradhan S; Das A; Singh H; Chaturvedi S; Singh K; Mishra R; Misra DP; Agarwal V
    Indian J Pediatr; 2020 Sep; 87(9):692-698. PubMed ID: 32314166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone acetylation as a therapeutic target.
    Selvi BR; Chatterjee S; Modak R; Eswaramoorthy M; Kundu TK
    Subcell Biochem; 2013; 61():567-96. PubMed ID: 23150268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models.
    Vianello S; Consolaro F; Bich C; Cancela JM; Roulot M; Lanchec E; Touboul D; Brunelle A; Israël M; Benoit E; de la Porte S
    FASEB J; 2014 Jun; 28(6):2603-19. PubMed ID: 24604079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential of histone deacetylase inhibitors for bladder cancer treatment.
    Tanji N; Ozawa A; Kikugawa T; Miura N; Sasaki T; Azuma K; Yokoyama M
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):959-65. PubMed ID: 21707293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.
    Hori YS; Kuno A; Hosoda R; Tanno M; Miura T; Shimamoto K; Horio Y
    J Pharmacol Exp Ther; 2011 Sep; 338(3):784-94. PubMed ID: 21652783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy.
    Balagopal P; Olney R; Darmaun D; Mougey E; Dokler M; Sieck G; Hammond D
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E530-9. PubMed ID: 16263771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Muscle ERRγ mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming.
    Matsakas A; Yadav V; Lorca S; Narkar V
    FASEB J; 2013 Oct; 27(10):4004-16. PubMed ID: 23781095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mammalian animal models for Duchenne muscular dystrophy.
    Willmann R; Possekel S; Dubach-Powell J; Meier T; Ruegg MA
    Neuromuscul Disord; 2009 Apr; 19(4):241-9. PubMed ID: 19217290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy.
    Palladino M; Gatto I; Neri V; Straino S; Smith RC; Silver M; Gaetani E; Marcantoni M; Giarretta I; Stigliano E; Capogrossi M; Hlatky L; Landolfi R; Pola R
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2867-76. PubMed ID: 24072696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactions between muscle stem cells, mesenchymal-derived cells and immune cells in muscle homeostasis, regeneration and disease.
    Farup J; Madaro L; Puri PL; Mikkelsen UR
    Cell Death Dis; 2015 Jul; 6(7):e1830. PubMed ID: 26203859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potential of HDAC inhibitors as cognitive enhancers.
    Gräff J; Tsai LH
    Annu Rev Pharmacol Toxicol; 2013; 53():311-30. PubMed ID: 23294310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated satellite cell number in Duchenne muscular dystrophy.
    Kottlors M; Kirschner J
    Cell Tissue Res; 2010 Jun; 340(3):541-8. PubMed ID: 20467789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.